ResearchSafe

Semax (Semax (ACTH 4-10 analog))

Category: Cognitive & Nootropic. Status: Research compound.

A synthetic peptide from ACTH(4-10) with Pro-Gly-Pro stabilization. Approved in Russia for stroke and cognitive disorders. Enhances attention, memory, and neuroplasticity.

How it works

Activates MC3/4R, increases BDNF and NGF, modulates dopamine/serotonin, enhances neuronal survival via TrkB, and promotes CREB-mediated neuroplasticity.

Key facts

  • Molecular weight: 813.9 Da
  • Half-life: 3-5 min (systemic) / extended (intranasal)
  • Bioavailability: Moderate (intranasal)
  • Storage: Solution: 2-8°C. Use within 30 days of opening.

Dosing overview

  • Typical dose: 200-600 mcg per dose
  • Frequency: 2-3x daily
  • Duration: 2-4 week courses
  • Route: Intranasal drops/spray

Protocol notes

  • Intranasal, split into 2-3 doses across the day.
  • The N-acetyl (NA-Semax) version is more potent/longer-acting, so doses run a bit lower.
  • Often paired with Selank.

Reported benefits

  • Enhanced attention/focus
  • Memory improvement
  • Neuroprotection (stroke)
  • BDNF/NGF upregulation
  • Improved learning
  • Optic nerve support

Possible side effects

  • Nasal irritation
  • Headache
  • Hair loss (very high doses, rare)
  • Irritability

Research

  • Semax neuroprotection in acute ischemic stroke (2021): Intranasal semax within 6h of stroke reduced infarct volume by 25% and improved outcomes at 30 days.
  • Cognitive enhancement by semax in healthy volunteers (2020): Improved working memory by 20% and selective attention by 30% in 14-day crossover study.

Compare Semax

Community discussions about Semax

Research and educational reference only. Not medical advice.